POST-TRANSPLANT DIABETES MELLITUS (PTDM) IN PATIENTS AFTER LIVER TRANSPLANTATION – DIAGNOSIS AND TREATMENT
Abstract
Liver transplantation is an effective method for treating end-stage liver failure and certain liver cancers. Survival after this procedure is associated with the development of comorbidities, including before diagnosed diabetes mellitus and new diagnosed post-transplant diabetes mellitus (PTDM). Its pathophysiology differs from that of type 2 diabetes in the general population and reflects a complex interplay between pre-existing metabolic vulnerability (e.g. obesity, insulin resistance, impaired fasting glucose), perioperative stressors, and chronic immunosuppression. Commonly used immunosuppressive drugs, such as calcineurin inhibitors (particularly tacrolimus), mTOR inhibitors, and glucocorticosteroids, affect not only pancreatic function but also contribute to weight gain and chronic inflammation. Therapeutic goals should therefore be individualized according to time since transplantation, comorbidity burden, risk of hypoglycemia, and liver graft and renal function.
Aim of the study: The objective of this study is to summarize recent literature on the diagnosis and treatment of PTDM and type 2 diabetes mellitus after liver transplantation.
Materials and methods: In this narrative review, we searched the PubMed database to analyze the latest evidence on the treatment and diagnosis of PTDM, and type 2 diabetes mellitus diagnosed before liver transplantation.
Results: We discuss diagnostic approaches as well as pharmacological and non-pharmacological treatment strategies for these metabolic disorders in patients receiving long-term immunosuppression.
Conclusions: Interdisciplinary care and integration of lifestyle interventions are essential to optimize metabolic and cardiovascular risk management in liver transplant recipients. There remains a strong need for further clinical trials evaluating the safety and efficacy of oral antidiabetic agents in this specific patient population.
References
Adam, R., Karam, V., Delvart, V., O’Grady, J., Mirza, D., Klempnauer, J., Castaing, D., Neuhaus, P., Jamieson, N., Salizzoni, M., Pollard, S., Lerut, J., Paul, A., Garcia-Valdecasas, J. C., Rodríguez, F. S. J., & Burroughs, A. (2012). Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). Journal of Hepatology, 57(3), 675–688. https://doi.org/10.1016/j.jhep.2012.04.015
Alicic, R. Z., Rooney, M. T., & Tuttle, K. R. (2017). Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12(12), 2032–2045. https://doi.org/10.2215/CJN.11491116
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Kosiborod, M. N., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., … Gabbay, R. A. (2024). 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S179–S218. https://doi.org/10.2337/dc24-S010
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., … Gabbay, R. A. (2024). 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S20–S42. https://doi.org/10.2337/dc24-S002
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Kushner, R. F., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., … Gabbay, R. A. (2024). 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes–2024. Diabetes Care, 47(Supplement_1), S145–S157. https://doi.org/10.2337/dc24-S008
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., … Gabbay, R. A. (2024). 13. Older Adults: Standards of Care in Diabetes—2024. Diabetes Care, 47(Supplement_1), S244–S257. https://doi.org/10.2337/dc24-S013
Baid, S., Cosimi, A. B., Lin Farrell, M., Schoenfeld, D. A., Feng, S., Chung, R. T., Tolkoff-Rubin, N., & Pascual, M. (2001). POSTTRANSPLANT DIABETES MELLITUS IN LIVER TRANSPLANT RECIPIENTS: RISK FACTORS, TEMPORAL RELATIONSHIP WITH HEPATITIS C VIRUS ALLOGRAFT HEPATITIS, AND IMPACT ON MORTALITY1: Transplantation, 72(6), 1066–1072. https://doi.org/10.1097/00007890-200109270-00015
Berkovic, M. C., Virovic-Jukic, L., Bilic-Curcic, I., & Mrzljak, A. (2020). Post-transplant diabetes mellitus and preexisting liver disease—A bidirectional relationship affecting treatment and management. World Journal of Gastroenterology, 26(21), 2740–2757. https://doi.org/10.3748/wjg.v26.i21.2740
Burra, P., Becchetti, C., & Germani, G. (2020). NAFLD and liver transplantation: Disease burden, current management and future challenges. JHEP Reports, 2(6), 100192. https://doi.org/10.1016/j.jhepr.2020.100192
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024). Drug-Drug Interactions Between Glucagon-Like Peptide 1 Receptor Agonists and Oral Medications: A Systematic Review. Drug Safety, 47(5), 439–451. https://doi.org/10.1007/s40264-023-01392-3
Cho, Y., Lee, M. J., Choe, E. Y., Jung, C. H., Joo, D. J., Kim, M. S., Cha, B. S., Park, J.-Y., & Kang, E. S. (2014). Statin therapy is associated with the development of new-onset diabetes after transplantation in liver recipients with high fasting plasma glucose levels. Liver Transplantation, 20(5), 557–563. https://doi.org/10.1002/lt.23831
Dimakos, J., Cui, Y., Platt, R. W., Renoux, C., Filion, K. B., & Douros, A. (2023). Concomitant Use of Sulfonylureas and β-Blockers and the Risk of Severe Hypoglycemia Among Patients With Type 2 Diabetes: A Population-Based Cohort Study. Diabetes Care, 46(2), 377–383. https://doi.org/10.2337/dc22-1584
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., … American Diabetes Association. (2023). 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023. Diabetes Care, 46(Supplement_1), S19–S40. https://doi.org/10.2337/dc23-S002
Grancini, V., Resi, V., Palmieri, E., Pugliese, G., & Orsi, E. (2019). Management of diabetes mellitus in patients undergoing liver transplantation. Pharmacological Research, 141, 556–573. https://doi.org/10.1016/j.phrs.2019.01.042
Hecking, M., Haidinger, M., Döller, D., Werzowa, J., Tura, A., Zhang, J., Tekoglu, H., Pleiner, J., Wrba, T., Rasoul-Rockenschaub, S., Mühlbacher, F., Schmaldienst, S., Druml, W., Hörl, W. H., Krebs, M., Wolzt, M., Pacini, G., Port, F. K., & Säemann, M. D. (2012). Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation. Journal of the American Society of Nephrology, 23(4), 739–749. https://doi.org/10.1681/ASN.2011080835
Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., De Vries, A. P. J., Porrini, E., Pacini, G., Port, F. K., Sharif, A., Saemann, M. D., & European-New-Onset Diabetes After Transplantation Working Group. (2013). Novel views on new-onset diabetes after transplantation: Development, prevention and treatment. Nephrology Dialysis Transplantation, 28(3), 550–566. https://doi.org/10.1093/ndt/gfs583
Heisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004). New Onset Diabetes Mellitus in Patients Receiving Calcineurin Inhibitors: A Systematic Review and Meta-Analysis. American Journal of Transplantation, 4(4), 583–595. https://doi.org/10.1046/j.1600-6143.2003.00372.x
Heit, J. J., Apelqvist, Å. A., Gu, X., Winslow, M. M., Neilson, J. R., Crabtree, G. R., & Kim, S. K. (2006). Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function. Nature, 443(7109), 345–349. https://doi.org/10.1038/nature05097
Honda, M., Asonuma, K., Hayashida, S., Suda, H., Ohya, Y., Lee, K., Yamamoto, H., Takeichi, T., & Inomata, Y. (2013). Incidence and risk factors for new‐onset diabetes in living‐donor liver transplant recipients. Clinical Transplantation, 27(3), 426–435. https://doi.org/10.1111/ctr.12103
Hu, S., & Lan, G. (2025). Comparative efficacy and safety of antidiabetic agents for post-transplant diabetes mellitus: A network meta-analysis. Frontiers in Medicine, 12, 1653147. https://doi.org/10.3389/fmed.2025.1653147
Johnston, O., Rose, C. L., Webster, A. C., & Gill, J. S. (2008). Sirolimus Is Associated with New-Onset Diabetes in Kidney Transplant Recipients. Journal of the American Society of Nephrology, 19(7), 1411–1418. https://doi.org/10.1681/ASN.2007111202
Kajosaari, L., Niemi, M., Neuvonen, M., Laitila, J., Neuvonen, P., & Backman, J. (2005). Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical Pharmacology & Therapeutics, 78(4), 388–399. https://doi.org/10.1016/j.clpt.2005.07.005
Kuo, H.-T., Sampaio, M. S., Ye, X., Reddy, P., Martin, P., & Bunnapradist, S. (2010). Risk Factors for New-Onset Diabetes Mellitus in Adult Liver Transplant Recipients, an Analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing Database. Transplantation, 89(9), 1134–1140. https://doi.org/10.1097/TP.0b013e3181d2fec1
Kurian, B., Joshi, R., & Helmuth, A. (2008). Effectiveness and Long-Term Safety of Thiazolidinediones and Metformin in Renal Transplant Recipients. Endocrine Practice, 14(8), 979–984. https://doi.org/10.4158/EP.14.8.979
Li, D.-W. (2015). Risk factors for new onset diabetes mellitus after liver transplantation: A meta-analysis. World Journal of Gastroenterology, 21(20), 6329. https://doi.org/10.3748/wjg.v21.i20.6329
Ling, Q., Xu, X., Xie, H., Wang, K., Xiang, P., Zhuang, R., Shen, T., Wu, J., Wang, W., & Zheng, S. (2016). New‐onset diabetes after liver transplantation: A national report from China Liver Transplant Registry. Liver International, 36(5), 705–712. https://doi.org/10.1111/liv.13042
Meneghini, L. F. (2013). Insulin therapy for type 2 diabetes. Endocrine, 43(3), 529–534. https://doi.org/10.1007/s12020-012-9817-6
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayes‐Genis, A., Boehm, M., Butler, J., Chioncel, O., Filippatos, G., Gustafsson, F., Jankowska, E. A., Kaski, J. C., Moura, B., Petrie, M. C., Ponikowski, P., Rakisheva, A., Ristic, A., Roubille, F., … Rosano, G. (2025). SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI. ESC Heart Failure, 12(6), 3806–3825. https://doi.org/10.1002/ehf2.15408
Mukuba, D., Mallik, R., & Chowdhury, T. A. (2026). Diabetes and transplantation. Clinical Medicine, 26(1), 100514. https://doi.org/10.1016/j.clinme.2025.100514
Munoz Pena, J. M., & Cusi, K. (2023). Posttransplant Diabetes Mellitus: Recent Developments in Pharmacological Management of Hyperglycemia. The Journal of Clinical Endocrinology & Metabolism, 109(1), e1–e11. https://doi.org/10.1210/clinem/dgad395
National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. (b.d.). LiverTox Clinical and Research Information on Drug-Induced Liver Injury. Pobrano https://www.ncbi.nlm.nih.gov/books/NBK547852/
Ninčević, V., Omanović Kolarić, T., Roguljić, H., Kizivat, T., Smolić, M., & Bilić Ćurčić, I. (2019). Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes. International Journal of Molecular Sciences, 20(23), 5831. https://doi.org/10.3390/ijms20235831
Peláez-Jaramillo, M. J., Cárdenas-Mojica, A. A., Gaete, P. V., & Mendivil, C. O. (2018). Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment. Diabetes Therapy, 9(2), 521–543. https://doi.org/10.1007/s13300-018-0374-8
Poitout, V., & Robertson, R. P. (2008). Glucolipotoxicity: Fuel Excess and β-Cell Dysfunction. Endocrine Reviews, 29(3), 351–366. https://doi.org/10.1210/er.2007-0023
Puri, P., & Kotwal, N. (2022). An Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist. Journal of Clinical and Experimental Hepatology, 12(2), 560–574. https://doi.org/10.1016/j.jceh.2021.09.010
Richardson, B., Khan, M. Q., Brown, S. A., Watt, K. D., & Izzy, M. (2022). Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management. Hepatology Communications, 6(6), 1250–1261. https://doi.org/10.1002/hep4.1876
Scheen, A. J. (2005). Drug Interactions of Clinical Importance with Antihyperglycaemic Agents: An Update. Drug Safety, 28(7), 601–631. https://doi.org/10.2165/00002018-200528070-00004
Scheen, A. J. (2012). DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials. Diabetes & Metabolism, 38(2), 89–101. https://doi.org/10.1016/j.diabet.2011.11.001
Scheen, A. J. (2014). Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opinion on Drug Metabolism & Toxicology, 10(6), 839–857. https://doi.org/10.1517/17425255.2014.902444
Sharif, A., Chakkera, H., De Vries, A. P. J., Eller, K., Guthoff, M., Haller, M. C., Hornum, M., Nordheim, E., Kautzky-Willer, A., Krebs, M., Kukla, A., Kurnikowski, A., Schwaiger, E., Montero, N., Pascual, J., Jenssen, T. G., Porrini, E., & Hecking, M. (2024). International consensus on post-transplantation diabetes mellitus. Nephrology Dialysis Transplantation, 39(3), 531–549. https://doi.org/10.1093/ndt/gfad258
Sharif, A., Hecking, M., De Vries, A. P. J., Porrini, E., Hornum, M., Rasoul-Rockenschaub, S., Berlakovich, G., Krebs, M., Kautzky-Willer, A., Schernthaner, G., Marchetti, P., Pacini, G., Ojo, A., Takahara, S., Larsen, J. L., Budde, K., Eller, K., Pascual, J., Jardine, A., … Säemann, M. D. (2014). Proceedings From an International Consensus Meeting on Posttransplantation Diabetes Mellitus: Recommendations and Future Directions. American Journal of Transplantation, 14(9), 1992–2000. https://doi.org/10.1111/ajt.12850
Van Hooff, J. P., Christiaans, M. H. L., & Van Duijnhoven, E. M. (2005). Tacrolimus and Posttransplant Diabetes Mellitus in Renal Transplantation. Transplantation, 79(11), 1465–1469. https://doi.org/10.1097/01.TP.0000157870.21957.E5
Van Laecke, S., Desideri, F., Geerts, A., Van Vlierberghe, H., Berrevoet, F., Rogiers, X., Troisi, R., De Hemptinne, B., Vanholder, R., & Colle, I. (2010). Hypomagnesemia and the risk of new-onset diabetes after liver transplantation. Liver Transplantation, 16(11), 1278–1287. https://doi.org/10.1002/lt.22146
van Raalte, D. H., & Diamant, M. (2014). Steroid diabetes: From mechanism to treatment? The Netherlands Journal of Medicine, 72(2), 62–72.
Vergès, B., & Cariou, B. (2015). mTOR inhibitors and diabetes. Diabetes Research and Clinical Practice, 110(2), 101–108. https://doi.org/10.1016/j.diabres.2015.09.014
Weir, G. C., & Bonner-Weir, S. (2004). Five Stages of Evolving Beta-Cell Dysfunction During Progression to Diabetes. Diabetes, 53(suppl_3), S16–S21. https://doi.org/10.2337/diabetes.53.suppl_3.S16
Yadav, A. D., Chang, Y.-H., Aqel, B. A., Byrne, T. J., Chakkera, H. A., Douglas, D. D., Mulligan, D. C., Rakela, J., Vargas, H. E., & Carey, E. J. (2013). New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. Journal of Transplantation, 2013, 1–7. https://doi.org/10.1155/2013/269096
Yale, J.-F., Aroda, V. R., Charbonnel, B., Sinclair, A. J., Trescoli, C., Cahn, A., Bigot, G., Merino-Trigo, A., Brulle-Wohlhueter, C., Bolli, G. B., & Ritzel, R. (2020). Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL versus glargine 100 U/mL: A patient-level meta-analysis examining older and younger adults with type 2 diabetes. Diabetes & Metabolism, 46(2), 110–118. https://doi.org/10.1016/j.diabet.2018.10.002
Zheng, K., Azhie, A., You, X., Naghibzadeh, M., Tan, E., Naimimohasses, S., Sridhar, V. S., Gupta, S., Chen, S., Dash, S., Tsien, C., Selzner, N., Lilly, L., Jaeckel, E., Woo, M., Singh, S., Cherney, D., & Bhat, M. (2024). GLUCAGON‐LIKE PEPTIDE ‐1 receptor agonists and SODIUM‐GLUCOSE COTRANSPORTER ‐2 inhibitors for the treatment of diabetes mellitus in liver transplant recipients. Diabetes, Obesity and Metabolism, 26(10), 4261–4272. https://doi.org/10.1111/dom.15769
Copyright (c) 2026 Kacper Karaban, Wojciech Żywiec, Michał Dorota
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
